Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron

NCT02294396 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02294396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02294396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postmarketing Study of Mirabegron in Japan: Long-term Add-on Therapy With Antimuscarinics in Patients With Overactive Bladder Treated With Mirabegron
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
October 28, 2014
Completion date
September 7, 2016
Enrollment
649 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder (oab)